1 completed, 1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Mivavotinib: new trials by email Literature Review of Mivavotinib trials Research Report on Mivavotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Mivavotinib - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, With and Without MyD88 and/or CD79B Mutations | Phase 2 | Terminated | Calithera Biosciences, Inc | 2 | 2022-06-23 | 2023-04-04 |
| TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors Mivavotinib, Paclitaxel, Pharmacokinetic Study - Advanced Malignant Solid Neoplasm, Ovarian Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 52 | 2019-03-05 | 2023-02-28 |
Ovarian Neoplasms (1) · Recurrence (1)
Calithera Biosciences, Inc (1) · M.D. Anderson Cancer Center (1)
United States (2)
Siqing Fu (1)
P30CA016672 (1)